SRS Capital Advisors Inc. Has $126,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

SRS Capital Advisors Inc. raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 74.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,702 shares of the medical research company’s stock after purchasing an additional 724 shares during the period. SRS Capital Advisors Inc.’s holdings in Edwards Lifesciences were worth $126,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Van ECK Associates Corp lifted its stake in Edwards Lifesciences by 7.7% in the third quarter. Van ECK Associates Corp now owns 126,764 shares of the medical research company’s stock valued at $8,951,000 after acquiring an additional 9,011 shares during the last quarter. Forum Financial Management LP acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $203,000. Asset Management One Co. Ltd. boosted its holdings in Edwards Lifesciences by 0.9% in the third quarter. Asset Management One Co. Ltd. now owns 239,392 shares of the medical research company’s stock worth $15,797,000 after purchasing an additional 2,188 shares in the last quarter. QRG Capital Management Inc. increased its position in Edwards Lifesciences by 66.6% during the third quarter. QRG Capital Management Inc. now owns 77,245 shares of the medical research company’s stock worth $5,097,000 after buying an additional 30,892 shares during the last quarter. Finally, Impax Asset Management Group plc raised its holdings in Edwards Lifesciences by 66.2% during the third quarter. Impax Asset Management Group plc now owns 12,964 shares of the medical research company’s stock valued at $855,000 after buying an additional 5,164 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 2.1 %

NYSE EW opened at $72.89 on Thursday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a market capitalization of $42.99 billion, a price-to-earnings ratio of 10.46, a PEG ratio of 4.82 and a beta of 1.10. The stock’s 50 day moving average is $72.45 and its two-hundred day moving average is $70.35. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $70.78, for a total value of $796,275.00. Following the completion of the transaction, the chief financial officer now owns 30,387 shares in the company, valued at approximately $2,150,791.86. The trade was a 27.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,739 shares of company stock valued at $2,799,104. 1.29% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wolfe Research lowered Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Evercore ISI dropped their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Truist Financial reaffirmed a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Finally, Piper Sandler upped their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.